Market Size of Arteriovenous Fistula Devices Industry
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 1.07 Billion |
| Market Size (2029) | USD 1.54 Billion |
| CAGR (2024 - 2029) | 7.50 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Arteriovenous Fistula Devices Market Analysis
The Arteriovenous Fistula Devices Market size is estimated at USD 1.07 billion in 2024, and is expected to reach USD 1.54 billion by 2029, growing at a CAGR of 7.5% during the forecast period (2024-2029).
Several factors drive the market for arteriovenous fistula (AVF) devices. A primary factor is the increasing prevalence of end-stage renal disease (ESRD), which often requires hemodialysis. AVFs are essential for ensuring reliable vascular access during these dialysis treatments. Furthermore, the growing adoption of minimally invasive procedures, including endovascular techniques and embolization, has further boosted the demand for AVF devices.
The rising incidence of ESRD, often associated with conditions like diabetes and hypertension, necessitates more efficient and effective dialysis access solutions. As more patients require dialysis, the demand for AV fistulas, which provide a reliable and long-term access point for hemodialysis, is increasing, driving the market's growth. For instance, as per Kidney Care Report 2023, in the United Kingdom, roughly 30,000 individuals depend on dialysis for survival, and annually, about 3,000 undergo kidney transplants. An estimated 3.25 million adults, accounting for over 10% of the adult population, live with chronic kidney disease (CKD) stages 3-5. Projections for 2033 indicate a rise in dialysis-dependent adults to around 33,845 and an increase in annual kidney transplants to about 3,615. Thus, the high burden of ESRD is expected to increase the demand for AVF to provide a reliable and long-term access point for hemodialysis, driving the market's growth.
In addition, as per the above context, by 2030, the incidence of ESRD is projected to double, influenced by factors like diabetes, hypertension, and an aging population in the United Kingdom. Additionally, the share of patients in the later stages of CKD is anticipated to rise from 45% to 51% in the coming decade. The increasing burden of end-stage renal disease (ESRD) is expected to drive the market for arteriovenous (AV) fistula devices, thereby boosting market growth.
Key players in the AVF device market are actively pursuing strategic initiatives to bolster the market's growth. For instance, in January 2023, Alucent Biomedical Inc. is committed to advancing its AlucentNVS technology, which is aimed at treating vascular diseases. The company initiated its ACTIVATE AVF study to assess the safety and feasibility of the AlucentNVS therapy for arteriovenous fistula (AVF) in patients with end-stage renal disease (ESRD).
The AlucentNVS therapy is designed to accelerate and improve the physiological and functional maturation of AVF devices. If successful, this therapy could provide more patients with timely and reliable access to essential dialysis treatments. Technological advancements enhance patient outcomes and reduce complications associated with AVF procedures, driving the demand for innovative AVF devices and fostering a positive market trend.
The growing burden of ESRD is significantly impacting the market for AV fistula devices. As the prevalence of kidney disease rises, combined with a clear preference for the benefits of AV fistulas, technological advancements, and supportive healthcare policies, the demand for these devices is expected to increase. However, surgical complications and risks are expected to hamper the market's growth.
